• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阐明贝佐妥单抗在……中与毒素B的结合特异性。 (你提供的原文似乎不完整,最后的“in.”后面应该还有具体内容)

Elucidation of bezlotoxumab binding specificity to toxin B in .

作者信息

Karnchanapandh Kun, Hanpaibool Chonnikan, Sanachai Kamonpan, Rungrotmongkol Thanyada

机构信息

Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, Thailand.

Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.

出版信息

J Biomol Struct Dyn. 2024 Feb-Mar;42(4):1617-1628. doi: 10.1080/07391102.2023.2201360. Epub 2023 Apr 26.

DOI:10.1080/07391102.2023.2201360
PMID:37098802
Abstract

or infection (CDI) is currently one of the major causes of epidemics worldwide. Toxin B from toxin B (TcdB) infection is the main target protein inhibiting CDI recurrence. Clinical research suggested that bezlotoxumab's (Bez) efficiency is significantly reduced in neutralizing the B2 strain compared to the B1 strain. The monoclonal antibody (mAb) functions by binding to the epitope 1 and 2 regions in the combined repetitive oligopeptide (CROP) domain. Some binding residues are distinctively different between B1 and B2 strains. In this work, we aimed to elucidate and compare insights into the interaction of toxins B1 and B2 in complex with Bez by using all-atom molecular dynamics (MD) simulations and binding free energy calculations. The predicted Δ values suggested that the antibody (Ab) could bind to toxin B1 significantly better than B2, supported by higher salt bridge and hydrogen bonding (H-bonding) interactions, as well as the number of contact residues between the two focused proteins. The toxin B1 residues important for binding with Bez were E1878, T1901, E1902, F1905, N1941, V1946, N2031, T2032, E2033, V2076, V2077, and E2092. The lower susceptibility of Bez towards toxin B2 was primarily due to a change of residue E2033 from glutamate to alanine (A2033) and the loss of E1878 and E1902 contributions, as determined by the intermolecular interaction changes from the dynamic residue interaction network (dRIN) analysis. The obtained data strengthen our understanding of Bez/toxin B binding.

摘要

艰难梭菌感染(CDI)是当前全球流行的主要原因之一。来自艰难梭菌毒素B(TcdB)感染的毒素B是抑制CDI复发的主要靶蛋白。临床研究表明,与B1菌株相比,bezlotoxumab(Bez)中和B2菌株的效率显著降低。单克隆抗体(mAb)通过与组合重复寡肽(CROP)结构域中的表位1和2区域结合发挥作用。B1和B2菌株之间的一些结合残基明显不同。在这项工作中,我们旨在通过全原子分子动力学(MD)模拟和结合自由能计算,阐明并比较毒素B1和B2与Bez复合物相互作用的见解。预测的Δ值表明,抗体(Ab)与毒素B1的结合明显优于B2,这得到了更高的盐桥和氢键(H键)相互作用以及两种目标蛋白之间接触残基数量的支持。与Bez结合重要的毒素B1残基为E1878、T1901、E1902、F1905、N1941、V1946、N2031、T2032、E2033、V2076、V2077和E2092。Bez对毒素B2敏感性较低的主要原因是,通过动态残基相互作用网络(dRIN)分析确定,残基E2033从谷氨酸变为丙氨酸(A2033),以及E1878和E1902贡献的丧失。所获得的数据加深了我们对Bez/毒素B结合的理解。

相似文献

1
Elucidation of bezlotoxumab binding specificity to toxin B in .阐明贝佐妥单抗在……中与毒素B的结合特异性。 (你提供的原文似乎不完整,最后的“in.”后面应该还有具体内容)
J Biomol Struct Dyn. 2024 Feb-Mar;42(4):1617-1628. doi: 10.1080/07391102.2023.2201360. Epub 2023 Apr 26.
2
Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.X 射线晶体学揭示艰难梭菌毒素 B 中和抗体 bezlotoxumab 的作用机制和表位。
J Biol Chem. 2014 Jun 27;289(26):18008-21. doi: 10.1074/jbc.M114.560748. Epub 2014 May 12.
3
Enhancing bezlotoxumab binding to toxin B2: insights from computational simulations and mutational analyses for antibody design.增强贝佐妥昔单抗与毒素B2的结合:基于计算模拟和突变分析的抗体设计见解
J Biomol Struct Dyn. 2024 Mar 21:1-11. doi: 10.1080/07391102.2024.2329785.
4
Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.贝洛妥珠单抗治疗与不良结局相关的艰难梭菌 BI 型感染的试验参与者的疗效。
Clin Infect Dis. 2021 Nov 2;73(9):e2616-e2624. doi: 10.1093/cid/ciaa1035.
5
Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.超高效设计锚蛋白重复蛋白抑制剂选择和表征艰难梭菌毒素 B。
PLoS Biol. 2019 Jun 24;17(6):e3000311. doi: 10.1371/journal.pbio.3000311. eCollection 2019 Jun.
6
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.贝佐洛托珠单抗预防复发性艰难梭菌感染:来自随机 III 期试验 MODIFY II 的 12 个月观察数据。
Clin Infect Dis. 2020 Aug 14;71(4):1102-1105. doi: 10.1093/cid/ciz1151.
7
Bezlotoxumab prevents extraintestinal organ damage induced by infection.贝洛妥珠单抗可预防 感染引起的肠道外器官损伤。
Gut Microbes. 2022 Jan-Dec;14(1):2117504. doi: 10.1080/19490976.2022.2117504.
8
Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.贝洛妥珠单抗预防复发性艰难梭菌感染的疗效、安全性和成本效益:系统评价和荟萃分析。
J Clin Gastroenterol. 2024 Apr 1;58(4):389-401. doi: 10.1097/MCG.0000000000001875.
9
Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.艰难梭菌毒素A中和抗体Actoxumab的表位与作用机制
J Mol Biol. 2017 Apr 7;429(7):1030-1044. doi: 10.1016/j.jmb.2017.02.010. Epub 2017 Feb 21.
10
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?阿卡西单抗+贝洛妥珠单抗联合治疗:对艰难梭菌治疗有何前景?
Expert Opin Biol Ther. 2018 Apr;18(4):469-476. doi: 10.1080/14712598.2018.1452908. Epub 2018 Mar 15.